Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
HELIOS BIOSCIENCES<br />
8 rue du Général Sarrail<br />
94010 CRÉTEIL Cedex - FRANCE<br />
Email: info@heliosbiosciences.com<br />
Web site: www.heliosbiosciences.com<br />
Contact:<br />
Dr. Jean Baptiste DUMAS MILNE EDWARDS<br />
In HELIOS BIOSCIENCES WE are convinced th<strong>at</strong> signalling p<strong>at</strong>hways are of<br />
outstanding importance to understand and cure diseases. Thus, we have developed<br />
an integr<strong>at</strong>ed system biology pl<strong>at</strong>form dedic<strong>at</strong>ed to the building of dynamic models of<br />
cell signalling. We use transcriptomic and/or proteomic and/or metabolic d<strong>at</strong>a. These<br />
dynamic models are used to select therapeutic targets and/or biomarkers. Our models<br />
can be used also to search for multi-targets.The technology th<strong>at</strong> we have designed<br />
has been used to develop models of immunostimul<strong>at</strong>ion of T lymphocytes, dendritic<br />
cells and also to build models of neurodegener<strong>at</strong>ive diseases. Using our models of<br />
immunostimul<strong>at</strong>ion we have selected and in vitro valid<strong>at</strong>ed Immunosuppressive drug<br />
targets which belong to a new p<strong>at</strong>hway.<br />
We offer an access to our dynamic modelling technology. Various option starting from<br />
the building of a dedic<strong>at</strong>ed model to the internalis<strong>at</strong>ion of the technology are proposed.<br />
We also look for partners to develop our new targets.<br />
HEMARINA<br />
Aéropôle Centre<br />
29600 MORLAIX - FRANCE<br />
Phone: +33 2 98 88 88 23<br />
Fax: +33 2 98 88 38 94<br />
Email: info@hemarina.com<br />
Web site: www.hemarina.com<br />
Contact: Jacques CHASSERIAU<br />
Hemarina is a biotechnology company developing a new gener<strong>at</strong>ion of universal<br />
oxygen carrier for therapeutical and industrial applic<strong>at</strong>ions.<br />
41
Change language